BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-118@catalystbrief.girapphe.com
DTSTAMP:20261117T181553Z
LAST-MODIFIED:20261117T181553Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Telix Pharmaceuticals (Innovations) Pty Limited — 68Ga-P
 SMA-11 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: PSMA PET Combined With MRI for the 
 Detection of PCa.\nSource: https://clinicaltrials.gov/study/NCT07052214\nh
 ttps://catalystbrief.girapphe.com/e/118?lang=en\nNot investment advice. Da
 tes may change.
URL:https://catalystbrief.girapphe.com/e/118?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
